An analysis of AI-powered devices that received FDA's "breakthrough" label shows a preference for big-picture, multi-problem ...
Iopofosine-131 has been granted breakthrough therapy designation by the FDA for relapsed or refractory Waldenstrom macroglobulinemia, indicating its potential to improve treatment outcomes. The phase ...
Alixorexton at all doses demonstrated significant improvements from baseline in mean sleep latency compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy ...
Treatment with TSND-201 was associated with statistically significant improvement in PTSD symptoms. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSND-201 ...
An Informational Overview of BIOptimizers' 7-Form Full-Spectrum Magnesium Formula for 2026, Including Supplement Facts, ...
Sonrotoclax, a BCL2 inhibitor, received FDA breakthrough therapy designation for relapsed or refractory mantle cell lymphoma, indicating its potential to transform patient outcomes. The drug is ...
The problem with this approach is that the first medication prescribed works only about 30% of the time, with the likelihood of success dropping with each subsequent attempt — to under 7% by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results